Bellmunt J - Search Results

1

ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.

Patard JJ, Pignot G, Escudier B, Eisen T, Bex A, Sternberg C, Rini B, Roigas J, Choueiri T, Bukowski R, Motzer R, Kirkali Z, Mulders P, Bellmunt J. Patard JJ, et al. Among authors: bellmunt j. Eur Urol. 2011 Oct;60(4):684-90. doi: 10.1016/j.eururo.2011.06.017. Epub 2011 Jun 24. Eur Urol. 2011. PMID: 21704448 Review.

2

Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.

Sternberg CN, Donat SM, Bellmunt J, Millikan RE, Stadler W, De Mulder P, Sherif A, von der Maase H, Tsukamoto T, Soloway MS. Sternberg CN, et al. Among authors: bellmunt j. Urology. 2007 Jan;69(1 Suppl):62-79. doi: 10.1016/j.urology.2006.10.041. Urology. 2007. PMID: 17280909 Review.

3

The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce.

Bellmunt J, Négrier S, Escudier B, Awada A, Aapro M; SIOG Taskforce. Bellmunt J, et al. Crit Rev Oncol Hematol. 2009 Jan;69(1):64-72. doi: 10.1016/j.critrevonc.2008.08.002. Epub 2008 Sep 5. Crit Rev Oncol Hematol. 2009. PMID: 18774306 Review.

4

EORTC-GU group expert opinion on metastatic renal cell cancer.

de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M. de Reijke TM, et al. Among authors: bellmunt j. Eur J Cancer. 2009 Mar;45(5):765-73. doi: 10.1016/j.ejca.2008.12.010. Epub 2009 Jan 20. Eur J Cancer. 2009. PMID: 19157861 Review.

5

Optimal management of metastatic renal cell carcinoma: an algorithm for treatment.

Bellmunt J, Flodgren P, Roigas J, Oudard S. Bellmunt J, et al. BJU Int. 2009 Jul;104(1):10-8. doi: 10.1111/j.1464-410X.2009.08563.x. Epub 2009 Apr 21. BJU Int. 2009. PMID: 19388982 Review.

6

Sunitinib in renal-cell carcinoma: expanded indications.

Choueiri TK, Bellmunt J. Choueiri TK, et al. Among authors: bellmunt j. Lancet Oncol. 2009 Aug;10(8):740. doi: 10.1016/S1470-2045(09)70185-8. Epub 2009 Jul 15. Lancet Oncol. 2009. PMID: 19615941 Review. No abstract available.

7

Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer.

Bellmunt J, Rosenberg JE, Choueiri TK. Bellmunt J, et al. Eur Urol. 2009 Oct;56(4):606-8. doi: 10.1016/j.eururo.2009.07.015. Epub 2009 Jul 22. Eur Urol. 2009. PMID: 19635642 No abstract available.

8

Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.

Negrier S, Jäger E, Porta C, McDermott D, Moore M, Bellmunt J, Anderson S, Cihon F, Lewis J, Escudier B, Bukowski R. Negrier S, et al. Among authors: bellmunt j. Med Oncol. 2010 Sep;27(3):899-906. doi: 10.1007/s12032-009-9303-z. Epub 2009 Sep 12. Med Oncol. 2010. PMID: 19757215 Clinical Trial.

9

Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma.

Porta C, Bellmunt J, Eisen T, Szczylik C, Mulders P. Porta C, et al. Among authors: bellmunt j. Cancer Treat Rev. 2010 Feb;36(1):16-23. doi: 10.1016/j.ctrv.2009.09.001. Epub 2009 Oct 9. Cancer Treat Rev. 2010. PMID: 19819078 Review.

10

Experience with sorafenib and the elderly patient.

Dutcher JP, Tannir N, Bellmunt J, Escudier B. Dutcher JP, et al. Among authors: bellmunt j. Med Oncol. 2010 Dec;27(4):1359-70. doi: 10.1007/s12032-009-9388-4. Epub 2009 Dec 31. Med Oncol. 2010. PMID: 20043216

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

546 results

Search Page

Filters